3.2175
0.93%
+0.0075
Ovid Therapeutics Inc stock is currently priced at $3.2175, with a 24-hour trading volume of 64,477.
It has seen a +0.93% increased in the last 24 hours and a +17.82% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $3.19 pivot point. If it approaches the $3.26 resistance level, significant changes may occur.
Ovid Therapeutics Inc Stock (OVID) Financials Data
Ovid Therapeutics Inc (OVID) Revenue 2024
OVID reported a revenue (TTM) of $391.70 thousand for the quarter ending December 31, 2023.
Ovid Therapeutics Inc (OVID) Net Income 2024
OVID net income (TTM) was -$52.34 million for the quarter ending December 31, 2023, a +3.38% increase year-over-year.
Ovid Therapeutics Inc (OVID) Cash Flow 2024
OVID recorded a free cash flow (TTM) of -$45.92 million for the quarter ending December 31, 2023, a +18.94% increase year-over-year.
Ovid Therapeutics Inc (OVID) Earnings per Share 2024
OVID earnings per share (TTM) was -$0.75 for the quarter ending December 31, 2023, a +2.60% growth year-over-year.
Ovid Therapeutics Inc Stock (OVID) Latest News
Over $2M Bet On NextNav? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
Benzinga
Poseida Therapeutics, Inc. (PSTX) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
GlobeNewswire Inc.
Ligand (LGND) Posts Long-Term Outlook, Updates Portfolio Progress
Zacks Investment Research
Ovid Therapeutics (OVID) Upgraded to Buy: Here's Why
Zacks Investment Research
Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates
GlobeNewswire Inc.
About Ovid Therapeutics Inc
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate which has completed Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome. It is also developing OV935, a drug candidate that is in Phase Ib/IIa trial for rare epileptic encephalopathies; preclinical-stage compounds for rare epilepsy disorders; and OV102, an intravenous formulation for indications in the clinical setting. The company has collaboration agreement with Takeda Pharmaceutical Company Limited. Ovid Therapeutics Inc. was founded in 2014 and is headquartered in New York, New York.
Cap:
|
Volume (24h):